Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
Yokosuka
Osamu
O
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D024882:Drug Resistance, Viral / Q000235:genetics; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D008134:Long-Term Care; D009154:Mutation / Q000235:genetics; D012008:Recurrence; D014779:Virus Replication / Q000235:genetics
D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine